Background {#Sec1}
==========

Acute respiratory infections (ARIs) are one of the most important causes of morbidity and mortality among newborns and infants. Due to their immature immune system, newborn infants show a high vulnerability with an average of about four ARIs during the first year of life \[[@CR1]\]. This number may be even higher in infants that were born preterm, and some data suggest that ARIs are the main reason for the rehospitalization of these children \[[@CR2]\]. Humoral immunity deficiency in newborns is caused by insufficient transplacental transfer of IgG and a lack of IgA and IgM in serum \[[@CR3]\]. Insufficient activation of complement systems and low concentration of its components lead to a low opsonic activity of blood and weakness of phagocytes \[[@CR3]\]. Immaturity of bone marrow cells may often result in neutropenia \[[@CR3]\]. Low sensitivity of T lymphocyte receptors to IL-1 and IL-2; T helper cells immaturity and poor interaction of T and B lymphocytes, resulting in low levels of antibody production in response to antigens; and insufficient production of interferon γ by CD4^+^ T cells define a weak resistance of preterm newborns against the bacterial flora, a trend to spreading of infections and a high susceptibility to viral infections \[[@CR3]\].

A link between the newborns' health status, the state of its intestinal flora, and immunity, respectively, was shown by several researchers \[[@CR4]--[@CR7]\]. The intestinal bacterial colonization in preterm infants depends on a number of factors---vaginal microbiota of the mother, breastfeeding profile, the conditions in the maternity hospital, perinatal pathological factors, nosocomial flora, and the use of antibiotics and other pharmaceutical agents. The microbiocoenosis is incomplete at the end of the adaptation period of preterm infants and this, in turn, is a basic principle for bacterial and viral infections \[[@CR3]\].

In modern neonatology, probiotics are widely used in daily practice. Probiotics consist of "live microorganisms which when administered in adequate amounts confer a health benefit on the host" \[[@CR8]\]. Several studies indicate that administering probiotics can have a favorable effect on the prevention of infections \[[@CR9]--[@CR13]\], although a series of randomized controlled trials also suggests that effects observed in one probiotic strain cannot be extrapolated to others \[[@CR14], [@CR15]\].

The probiotic *Escherichia coli* strain Nissle 1917 (EcN) has no pathogenic characteristics \[[@CR16]\], is non-invasive \[[@CR17]\], and is capable to colonize the intestinal tract for longer periods \[[@CR18]--[@CR20]\]. Due to its wide spectrum of positive and clinically relevant characteristics and its great tolerance \[[@CR21]--[@CR26]\], EcN has been approved as a medical drug under the brand name Mutaflor^®^ Suspension (Ardeypharm GmbH, Herdecke, Germany) in various countries, including the Ukraine.

One particularly interesting and important property of EcN is its broad immunomodulatory effect on the non-specific and specific immunological system. EcN stimulates the systemic production of antibodies of mucous-associated B lymphocytes and induces the systemic production of antibodies (IgM, IgA) in adults as well as in full-term and premature children \[[@CR27]--[@CR30]\]. Interestingly, early administration of secretory IgA antibodies can protect children from infections \[[@CR31]\]. In combination, these findings make it reasonable to assume that EcN may increase the immune competence in preterm newborn infants, thereby reducing the risk of acquiring infections. However, clinical data supporting or refuting this hypothesis are, to our knowledge, not available. Therefore, the aim of the present pilot trial was to collect first data on the efficacy and safety of EcN treatment to prevent ARIs in late preterm newborns.

Methods {#Sec2}
=======

Study design and conduct {#Sec3}
------------------------

The present trial was a monocentric, prospective, and open-labelled clinical trial with a corresponding untreated control group, conducted in Odessa, Ukraine. The trial consisted of two parts, a newborn phase (time point of inclusion until day 28 of life) and a follow-up phase (day 29 of life until the end of the first year of life). Criteria for trial entry were signed informed consent of the child's legal guardian(s), first degree of prematurity (i.e., functionally mature and gestational age 35--36 weeks), intention of the mother to exclusively breast-feed her child during the newborn phase of the trial, and a newborn's age of 12--24 h of life at enrollment. Infants were excluded in case of non-fulfilment of one inclusion criteria, perinatal asphyxia or any perinatal pathological disease or defect (e.g., congenital birth defect, perinatal encephalopathy, other infectious disease, respiratory distress syndrome, and TORCH infections (Toxoplasmosis; Other, i.e., syphilis, varicella-zoster, parvovirus B19; Rubella; Cytomegalovirus; and Herpes infections \[[@CR32]\])), blood analysis results with clinically significant changes (i.e., deviations from mean values larger than ± 2 SD that are probably or possibly related to any underlying pathological condition), or intention to feed the child other pro- or prebiotics during the newborn phase of the trial. Eligible preterm newborns that were born in Odessa Maternity Hospital No. 5, Odessa, Ukraine, were included in this trial. Further examinations were carried out in health care centers of the Odessa region.

Enrolled children were either assigned to the treatment group (EcN) or the control group in an alternating manner by each participating investigator. Infants of the treatment group received an orally administered daily dosage of 1 ml Mutaflor^®^ Suspension, containing 10^8^ colony-forming units of *E*. *coli* strain Nissle 1917 per milliliter, during the first 7 days of life, and 1 ml of the same suspension three times a week from day 8 to 21. Thus, the application of Mutaflor^®^ Suspension complied with the dosage scheme of the approved medical product. Infants of the control group remained untreated and were just observed.

The trial comprised an initial examination (day 0), during which clinical, demographic, and somatic characteristics of the newborn were recorded (Table [1](#Tab1){ref-type="table"}). During the newborn phase, visits were carried out on days 7 and 21, and phone contacts took place on days 14 and 28. The follow-up observations took place as part of the conventional preventive checkups carried out at the ages of 6 and 12 months in Ukraine. Efficacy and safety data were recorded based on hospital medical records (if available) and parental reporting. A flow chart is presented in Fig. [1](#Fig1){ref-type="fig"}.Table 1Baseline characteristics of children enrolled in the study of efficacy and safety of EcN for immunity improvement in late preterm newbornsCharacteristicsEcN (*N* = 30)Control (*N* = 32)Gestational age at birth (weeks)35.5 ± 0.535.5 ± 0.5Age at inclusion (hours)17.3 ± 3.817.4 ± 3.3SexFemale14 (46.7)15 (46.9)Male16 (53.3)17 (53.1)Type of birthVaginal28 (93.3)26 (81.3)Caesarean2 (6.7)6 (18.8)Birth weight (g)2400 ± 1222396 ± 77Birth length (cm)45.2 ± 0.845.2 ± 0.9APGAR scoresI7.5 ± 0.57.6 ± 0.6II8.1 ± 0.38.1 ± 0.3Data are mean ± SD or number (%)*SD* standard deviation, *APGAR score* Appearance, Pulse, Grimace, Activity, Respiration scoreFig. 1Flowchart showing the timeline of the trial and the measurement schedule. ARI acute respiratory infection

The primary variable to assess efficacy of EcN for immunity improvement in preterm newborns was the number of participants with at least one acute respiratory infection during the newborn phase, i.e., during the first 28 days of life. Acute rhinitis, acute rhinopharyngitis, acute bronchitis, acute bronchiolitis, and pneumonia were counted as ARIs. As secondary efficacy variables, the number of ARI events and the number and duration of hospitalizations caused by ARIs during the newborn phase were documented. A further secondary objective of the present trial was to explore whether early EcN treatment has also a long-term effect on infant immunity. Therefore, all measures were also taken at the ages of 6 and 12 months.

The safety of EcN was evaluated by quantifying the number of adverse events (AEs) throughout the entire trial period, i.e., all untoward medical occurrences except the ARIs considered as primary efficacy variables. AEs were regarded as drug related if causality due to the study medication was rated "certain," "probable," or "possible" (according to the WHO Collaborating Centre for International Drug Monitoring) by the investigators. As a further safety measure, the somatic development, quantified by body weight and body length, was recorded at the ages of 6 and 12 months.

Figure [1](#Fig1){ref-type="fig"} provides an overview of the points in time when efficacy and safety measures were taken.

Participants' sufficient compliance to the trial protocol was defined as a complete lack of treatment with respect to the study medication for participants of the control group and an intake of at least 75% of the planned trial medication for participants of the treatment group.

Statistical analysis {#Sec4}
--------------------

Counts, means, frequencies, standard deviations, and 95% confidence intervals were calculated for the recorded data according to applicability. The data used to calculate the values at 6 months of life also contained the data already recorded during the first 28 days. Similarly, reported values after 12 months of life were calculated from *all* the data collected between the time of inclusion and 12 months of life.

Categorical data were compared by applying chi-square tests with Yates's correction and quantitative data by using the Mann-Whitney *U* tests.

The relative risk (RR), the relative risk reduction (RRR), and the number needed to treat (NNT) were calculated from the "number of participants with at least one ARI". Analyses were performed in Statistica 7.0 or Microsoft Excel and the significance level *α* was set at *p* \< 0.05.

Results {#Sec5}
=======

Participants {#Sec6}
------------

Between 19 March and 15 September 2011, a total of 62 late preterm newborns of Caucasian race were included into the trial and either assigned to the EcN (*N* = 30) or the control (*N* = 32) group (Fig. [2](#Fig2){ref-type="fig"}). The follow-up of the last participant ended on the 12 October 2012. On average, children of the two trial arms showed no substantial differences in any of the clinical, demographic, or somatic characteristics recorded during initial examination (Table [1](#Tab1){ref-type="table"}). All participants complied with the trial protocol, such that ITT and PP analyses of all data revealed equal results.Fig. 2Flowchart showing the allocation of subjects

Efficacy and safety of EcN for immunity improvement in late preterm newborns during the first 28 days of life (newborn phase) {#Sec7}
-----------------------------------------------------------------------------------------------------------------------------

Analysis of the primary outcome measure revealed a significant difference between the two trial arms, with fewer participants suffering from at least one ARI during the first 28 days of life in the EcN than in the control group (Fig. [3](#Fig3){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}). The risk to contract an ARI during the first month of life was 77% lower in the EcN than that in the control group, and the corresponding number needed to treat was 3.Fig. 3Result of primary efficacy measure. Shown are the numbers of participants with at least one ARI during the first 28 days of life for the EcN and the control group, respectivelyTable 2Results of the study of efficacy and safety of EcN for immunity improvement in late preterm newbornsAfter 28 days of lifeAfter 6 months of lifeAfter 12 months of lifeEcN (*N* = 30)Control (*N* = 32)EcN (*N* = 30)Control (*N* = 32)EcN (*N* = 30)Control (*N* = 32)Efficacy measures Total number and % of participants with at least 1 ARI3 (10.0)14 (43.7)15 (50.0)23 (71.9)23 (76.7)30 (93.8)*Χ*^2^~cor.~ = 7.25; *p* = 0.008Χ^2^~cor.~ = 2.27; *p* = 0.132Χ^2^~cor.~ = 1.32; *p* = 0.251 Mean number of ARI events0.10\
− 0.01--0.210.44\
0.26--0.610.50\
0.31--0.680.94\
0.69--1.190.90\
0.68--1.121.31\
1.08--1.54*z* = 2.28, *p* = 0.02*z* = 2.21, *p* = 0.03*z* = 2.11, *p* = 0.03 Mean number of hospitalizations due to ARIs0.03\
− 0.03--0.010.34\
0.18--0.510.13\
0.01--0.260.53\
0.33--0.730.27\
0.11--0.430.56\
0.37--0.76*z* = 2.01, *p* = 0.04*z* = 2.50, *p* = 0.01*z* = 1.84, *p* = 0.07 Mean duration of hospitalizations due to ARIs (days)0.27\
− 0.26--0.792.16\
0.98--3.341.20\
0.03--2.374.06\
2.48--5.642.43\
0.86--4.014.21\
2.66--5.78*z* = 1.85, *p* = 0.06*z* = 2.40, *p* = 0.02*z* = 1.59, *p* = 0.11 RR0.230.700.82 RRR0.770.300.18 NNT356Safety measures Total number of AEs0623212830 Total number of drug- related AEs000000 Mean body weight (g)N/AN/A6623 ± 2686419 ± 1649765 ± 4469634 ± 532 Mean body length (cm)N/AN/A61.4 ± 1.161.2 ± 0.973.0 ± 1.273.3 ± 1.4Data are numbers (%), means and CI, means ± SD, or epidemiological indices. Means of efficacy measures were always calculated from cumulative data. For details, see the "[Statistical analysis](#Sec4){ref-type="sec"}" section*%* frequency, *CI* 95% confidence intervals, *SD* standard deviation, *ARI* acute respiratory infection, *RR* relative risk, *RRR* relative risk reduction, *NNT* number needed to treat

Furthermore, exploratory comparisons suggest that the average number of ARIs, the average number of hospitalizations caused by ARIs, and the mean duration of such hospitalizations were lower in the group treated with EcN compared to the control group (Fig. [4](#Fig4){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}). Table [3](#Tab3){ref-type="table"} provides an overview of the type and number of ARIs that occurred.Fig. 4Exploratory results of secondary efficacy measures. Shown are the mean numbers of ARIs (**a**), the mean numbers of hospitalizations due to ARIs (**b**), and the mean durations of hospitalizations due to ARIs (**c**) after 28 days, 6 months, and 12 months for the EcN and the control group, respectively. Error bars represent 95% confidence intervals. As statistical analyses of secondary efficacy variables are only performed for explorative purposes, given *p* values are not corrected for α-error inflationTable 3Overview of the type and number of ARIs that occurred in the study of efficacy and safety of EcN for immunity improvement in late preterm newbornsAfter 28 days of lifeAfter 6 months of lifeAfter 12 months of lifeEcNControlEcNControlEcNControlType of ARI Acute rhinitis0235611 Acute rhinopharyngitis23771110 Acute bronchitis17312715 Acute bronchiolitis001212 Pneumonia021424Total31415302742Data are cumulative counts of occurred infections*ARI* acute respiratory infection

During the first 28 days of life, none of the children in the EcN group suffered from an AE, whereas six adverse events were recorded in the control group (Table [2](#Tab2){ref-type="table"}; kind of AE (no. of occurrences in EcN group/no. of occurrences in control group): infant colic (0/3); constipation (0/1); diarrhea (0/1); diaper dermatitis (0/1)).

Efficacy and safety of EcN for immunity improvement in late preterm newborns during the first year of life (follow-up phase) {#Sec8}
----------------------------------------------------------------------------------------------------------------------------

Explorative analyses of the data obtained after 6 and 12 months of life revealed that the risk to suffer from an ARI was still 30 and 18% lower in the EcN group compared to that in the untreated control group (Table [2](#Tab2){ref-type="table"}). However, the number of participants that experienced at least one ARI did not show any meaningful difference between the EcN and the control group anymore, neither after 6 nor after 12 months of life (Table [2](#Tab2){ref-type="table"}).

In contrast, the average number of ARI events and the average number and duration of hospitalizations caused by ARIs mostly appeared to be still different between the two trial arms, with the EcN group having a health advantage over the control group (Fig. [4](#Fig4){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}). Table [3](#Tab3){ref-type="table"} provides an overview of the type and number of ARIs that occurred.

The number of AEs reported during the entire trial was not considerably different (Table [2](#Tab2){ref-type="table"}; kind of AE (no. of occurrences in EcN group/no. of occurrences in control group): *at 12 months of age*: infant colic (7/6); acute enterocolitis (2/3); constipation (5/4); diarrhea (0/1); regurgitation (2/3); acute otitis media (2/2); diaper dermatitis (0/1); atopic dermatitis (3/2); changed blood parameter (0/1); weight deficiency (2/2); iron deficiency anemia stage 1 (2/3); perinatal encephalopathy; diagnosed only 3--5 weeks after inclusion into the trial (3/2)). Importantly, the investigators judged none of the adverse events as related to treatment. Children's somatic development, quantified by body weight and body length, was according to age \[[@CR33]\] and comparable between the two trial arms (Table [2](#Tab2){ref-type="table"}).

Discussion {#Sec9}
==========

The present pilot trial provides first evidence that *Escherichia coli* strain Nissle 1917 is an effective and safe probiotic that may improve immune competence in late preterm newborns. The evaluation of the primary efficacy criterion revealed that treatment of late preterm newborns with EcN suspension reduced their risk to contract an ARI during the first 28 days of life by 77% in comparison to children that remained untreated, a reduction that is substantial and clinically relevant (Table [2](#Tab2){ref-type="table"}). Thus, our findings are in line with recently published Cochrane reviews that summarize the general positive effect of probiotics in preventing the infection with acute respiratory disease \[[@CR34], [@CR35]\].

During the first 28 days, i.e., in a timely close correlation with the EcN administration, no adverse event could be detected in the group of children treated with EcN. Thus, EcN can be assessed as safe and well tolerated by preterm newborns with a gestational age of 35--36 weeks. In addition, the total number of adverse events reported during the first year of life was comparably low in both groups, being 28 and 30 in the EcN and the control group, respectively. None of these adverse events was judged as drug related. Similarly, children of both groups showed a normal and comparable somatic development. These data indicate that EcN treatment bears no safety risks.

EcN is able to colonize the intestinal tract. It was detected in the stool of adults up to 48 weeks \[[@CR20]\] and in the stool of healthy newborns up to 6 months after the intake of EcN was stopped \[[@CR24]\]. Therefore, it has been suggested that the infection prophylactic effect of EcN may even persist if the last EcN administration is already some time ago. To investigate this explorative hypothesis, variants of the primary efficacy variable, namely the numbers of children that suffered from at least one ARI during the first 6 and 12 months of life, were compared between the EcN and the control group. Interestingly, it appeared that the number of children with at least one ARI was no longer different between the EcN and the control group, neither after 6 nor after 12 months of age (Table [2](#Tab2){ref-type="table"}). Hence, a single EcN administration period, as used in the present study, seems not sufficient to prevent children from contracting a single ARI during the first 6 months of life. Future studies may therefore consider investigating whether a constant or at least repeated administration of EcN may be able to prolong the infection-free period.

The exploratory analysis of the further secondary efficacy variables led to additional interesting observations: The average number of ARIs, the average number of hospitalizations due to ARIs, and the mean duration of these hospitalizations during the first 28 days of life all tend to be reduced by an early treatment with EcN. Overall, most of these trends seem to persist until the ages of 6 and 12 months, making it possible to speculate about a potential long-term benefit of an early postnatal EcN treatment.

Although these findings are certainly interesting and add to our knowledge of the health-promoting properties of EcN, it needs to be considered that they are just of explorative nature. Similarly, limitations in the study design, like, for example, the comparatively small sample size or the fact that the study was not randomized and open-labeled, must be taken into account when drawing conclusions from the present data. Nonetheless, we believe that our findings provide good first evidence that early-life EcN administration is able to prevent ARIs in late preterm newborns. Therefore, our study may serve as a good basis for the design of future larger trials that should be conducted randomized, blinded, and placebo-controlled in order to confirm the present findings under the highest scientific standards.

Investigators planning such studies should also consider adjustments and further development of the study protocol. For example, it would be interesting to investigate whether a constant or repeated administration of EcN during the first year of life may be able to further increase the infection prophylactic effects of EcN (see above). In addition, it might be worth to also record data on the duration and severity of the infections that occur, as these data may allow a more detailed description of the health-promoting properties of EcN. However, collection of such data may require detailed written documentation by the parents at the time of the infection (study diary) and systematic collection of medical records, in order to minimize the potential impact of recall biases. Finally, it may be recommended to also record data on other factors that are known to affect a child's susceptibility to acquiring infections. For example, the duration of breastfeeding may act as a confounding variable in the given context and should therefore be taken into account in future studies, when analyzing the efficacy of EcN to prevent ARIs in newborns, infants, and toddlers.

Conclusions {#Sec10}
===========

In summary, our results provide the first evidence that administration of EcN directly after birth can reduce the risk of contracting an ARI in late preterm newborns during the first month of their life. EcN suspension is characterized by an excellent individual tolerance and the absence of adverse drug reactions. Additional explorative findings support the impression that EcN may be an effective and safe probiotic to prevent ARIs and may provoke speculations about a potential long-term benefit of a 3-week EcN administration starting right after birth. Although the limitations of the current trial need to be considered when drawing conclusions from the present data, it may still serve as a good basis when preparing future larger trials that are required to confirm the present findings under the highest scientific standards.
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